Skip to main content

Severe Hypertriglyceridemia

8
Pipeline Programs
6
Companies
18
Clinical Trials
3 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
4
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
3100%
+ 7 programs with unclassified modality

On Market (1)

Approved therapies currently available

Arrowhead Pharmaceuticals
REDEMPLOApproved
plozasiran
Arrowhead Pharmaceuticals
APOC-III-directed RNA Interaction [EPC]subcutaneous2025

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Arrowhead Pharmaceuticals
2 programs
1
1
1
REDEMPLO(plozasiran)Phase 35 trials
ARO-APOC3Phase 24 trials
Active Trials
NCT06347003Active Not Recruiting446Est. Sep 2026
NCT05089084Completed75Est. Apr 2026
NCT04998201Completed353Est. Aug 2023
+6 more trials
Doer Biologics
Doer BiologicsChina - Hangzhou
2 programs
1
1
DR10624 Subcutaneous InjectionPhase 31 trial
DR10624 InjectionPhase 22 trials
Active Trials
NCT07693777Not Yet Recruiting480Est. Dec 2029
NCT06555640Completed79Est. Aug 2025
NCT07680829Not Yet Recruiting378Est. Oct 2030
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
1
1
EpanovaPhase 21 trial
EpanovaPhase 11 trial
Active Trials
NCT02189252Completed30Est. Jul 2015
NCT01208961Completed54Est. Nov 2010
Prevail Therapeutics
1 program
1
SolbinsiranPhase 21 trial
Active Trials
NCT07269210Recruiting60Est. Aug 2027
Ionis Pharmaceuticals
3 programs
OlezarsenPHASE_3RNA Therapeutic1 trial
OlezarsenPHASE_3RNA Therapeutic1 trial
OlezarsenPHASE_3RNA Therapeutic1 trial
Active Trials
NCT05079919Completed617Est. Jul 2025
NCT05552326Completed446Est. Sep 2025
NCT05681351Active Not Recruiting885Est. Mar 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Doer BiologicsDR10624 Injection
Doer BiologicsDR10624 Subcutaneous Injection
Arrowhead Pharmaceuticalsplozasiran
Arrowhead Pharmaceuticalsplozasiran
Arrowhead Pharmaceuticalsplozasiran
Arrowhead PharmaceuticalsARO-APOC3
Arrowhead Pharmaceuticalsplozasiran
Ionis PharmaceuticalsOlezarsen
Ionis PharmaceuticalsOlezarsen
Arrowhead PharmaceuticalsARO-APOC3
Ionis PharmaceuticalsOlezarsen
Prevail TherapeuticsSolbinsiran
Doer BiologicsDR10624 Injection
Arrowhead PharmaceuticalsARO-APOC3
Arrowhead PharmaceuticalsARO-APOC3

Showing 15 of 17 trials with date data

Clinical Trials (18)

Total enrollment: 7,056 patients across 18 trials

NCT07693777Doer BiologicsDR10624 Injection

A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

Start: Aug 2026Est. completion: Dec 2029480 patients
Phase 3Not Yet Recruiting
NCT07680829Doer BiologicsDR10624 Subcutaneous Injection

A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia

Start: Aug 2026Est. completion: Oct 2030378 patients
Phase 3Not Yet Recruiting
NCT06880770Arrowhead Pharmaceuticalsplozasiran

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

Start: Apr 2025Est. completion: Jun 2029288 patients
Phase 3Recruiting
NCT06822790Arrowhead Pharmaceuticalsplozasiran

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

Start: Apr 2025Est. completion: Jul 2028869 patients
Phase 3Recruiting
NCT06347016Arrowhead Pharmaceuticalsplozasiran

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Start: Jul 2024Est. completion: Sep 2026311 patients
Phase 3Active Not Recruiting
NCT06347003Arrowhead PharmaceuticalsARO-APOC3

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Start: Jul 2024Est. completion: Sep 2026446 patients
Phase 3Active Not Recruiting
NCT06347133Arrowhead Pharmaceuticalsplozasiran

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Start: May 2024Est. completion: Sep 20261,456 patients
Phase 3Active Not Recruiting
NCT05681351Ionis PharmaceuticalsOlezarsen

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Start: Dec 2022Est. completion: Mar 2027885 patients
Phase 3Active Not Recruiting
NCT05552326Ionis PharmaceuticalsOlezarsen

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Start: Aug 2022Est. completion: Sep 2025446 patients
Phase 3Completed
NCT05089084Arrowhead PharmaceuticalsARO-APOC3

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Start: Dec 2021Est. completion: Apr 202675 patients
Phase 3Completed
NCT05079919Ionis PharmaceuticalsOlezarsen

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Start: Oct 2021Est. completion: Jul 2025617 patients
Phase 3Completed
NCT07269210Prevail TherapeuticsSolbinsiran

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

Start: Dec 2025Est. completion: Aug 202760 patients
Phase 2Recruiting
NCT06555640Doer BiologicsDR10624 Injection

A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

Start: Aug 2024Est. completion: Aug 202579 patients
Phase 2Completed
NCT04998201Arrowhead PharmaceuticalsARO-APOC3

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

Start: Sep 2021Est. completion: Aug 2023353 patients
Phase 2Completed
NCT04720534Arrowhead PharmaceuticalsARO-APOC3

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Start: May 2021Est. completion: Aug 2023229 patients
Phase 2Completed
NCT01208961AstraZenecaEpanova

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

Start: Sep 2010Est. completion: Nov 201054 patients
Phase 2Completed
NCT02189252AstraZenecaEpanova

An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis

Start: Oct 2014Est. completion: Jul 201530 patients
Phase 1Completed
NCT06796426Arrowhead Pharmaceuticalsplozasiran

Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

N/AAvailable

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 7,056 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.